Chronic Myeloid Leukemia TKI Resistance and Molecular Testing Insights at LeukO 2026
Chronic myeloid leukemia (CML) management involves navigating treatment resistance driven by BCR::ABL1 mutations, where a slow molecular response does not automatically indicate treatment failure. According to reporting from the LeukO 2026 Global Virtual Congress on Leukemias, organized by OncoDaily, premature discontinuation of tyrosine kinase inhibitors (TKIs) can expose patients to unnecessary toxicity. Giuseppe Saglio, Emeritus Professor of Hematology and Internal Medicine at the University of Turin, Italy, outlined that selecting the strongest TKI is not always the optimal approach, as age, comorbidities, tolerability, and individual treatment goals dictate long-term success.
Evaluating First-Line TKI Selection Based on Patient Age and Goals
BCR::ABL1 tyrosine kinase inhibition remains the core of CML treatment, yet patient demographics heavily influence drug choice. Italian clinical practice data presented by Saglio showed that approximately half of patients begin treatment with imatinib, while younger patients predominantly receive second-generation TKIs to pursue deep molecular responses and potentially attempt treatment-free remission.
Discontinuation Patterns and Toxicity Versus Resistance
Data from more than 1,500 patients highlight distinct discontinuation patterns across different TKIs. Approximately 30% of patients receiving imatinib or dasatinib discontinued their initial treatment during follow-up, whereas nilotinib showed greater treatment persistence in the population presented. Dasatinib discontinuation is frequently driven by intolerance, particularly pleural effusion, which affects roughly 20% of dasatinib-treated patients compared to 10% of those on nilotinib. Conversely, resistance occurs more frequently with imatinib than with second-generation TKIs, requiring clinicians to differentiate between toxicity and drug resistance before altering therapy.
Interpreting Molecular Response Milestones and Avoiding Premature Switches
The 2025 European LeukemiaNet (ELN) recommendations establish a refined, individualized framework for assessing treatment response across three categories: favorable, warning, and unfavorable. Long-term findings from the German CML Study IV demonstrate that patients missing early molecular milestones can still achieve favorable long-term survival on their initial treatment if transcript levels remain stable or improve. Persistent high disease burden, however, remains concerning, particularly when BCR::ABL1 levels exceed 10% after 12 months. Before modifying treatment, clinicians examine molecular trends, assess adherence, review dose adjustments, and evaluate patient comorbidities.
Identifying BCR::ABL1 Kinase Domain Mutations and Alternative Drug Resistance
Resistance mechanisms generally involve either the failure of a TKI to effectively inhibit BCR::ABL1 kinase activity due to structural mutations or inadequate intracellular drug exposure, or the emergence of independent survival mechanisms like clonal evolution. Kinase domain mutations directly impact TKI selection, with the T315I mutation preventing inhibition by conventional agents and making ponatinib an important alternative. The targeted agent asciminib binds to the ABL1 myristoyl pocket rather than the ATP-binding site, offering efficacy against certain ATP-competitive inhibitor resistances. Nevertheless, research has identified mutations such as M244V and F359V outside the myristoyl pocket that can interfere with asciminib activity, while compound mutations involving multiple alterations simultaneously can induce multi-TKI resistance.
Frequently Asked Questions About CML Management and Resistance
Why does a slow molecular response not always mean a treatment has failed?
Transcript levels can continue to decline over time even if a patient misses an early milestone, allowing them to achieve meaningful long-term disease control without switching therapies.
How does asciminib differ from traditional tyrosine kinase inhibitors?
Traditional TKIs interact with the ATP-binding site of the kinase, whereas asciminib binds to the ABL1 myristoyl pocket to stabilize an inactive conformation of BCR::ABL1.
What clinical factors separate imatinib usage from second-generation TKI prescriptions?
Physicians frequently prescribe second-generation TKIs to younger patients with a mean age of 51 to target deep molecular responses, while older patients with a mean age of 66 are more frequently treated with imatinib to prioritize long-term tolerability.
What challenges do compound mutations present for CML patients?
Compound mutations involve two or more mutations within the same BCR::ABL1 molecule, conferring simultaneous resistance to multiple TKIs and limiting sequential treatment options.
Worth a look